bearish
Ilyang Pharmaceutical (007570 KS): Key Drugs Facing Increasing Competition
604 Views23 Feb 2022 18:18
SUMMARY
- Ilyang Pharmaceutical Co., (007570 KS) shares have plunged 19% since we published our bearish insight on the company on November 2, 2021.
- We are still bearish on Ilyang Pharmaceutical as both of its key drugs, Noltec and Supect are facing increasing competition from new generation treatments.
- Q4 provisional results indicate sequential deceleration in revenue, operating profit, and net profit. Recently, one institutional shareholder has reduced stake holding in the company.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Ilyang Pharmaceutical (007570 KS): Key Drugs Facing Increasing Competition23 Feb 2022
- Ilyang Pharmaceutical (007570 KS): Leukemia Drug Commercialization Concerns Still Persist02 Nov 2021
x